Cornerstone Therapeutics Inc. (NASDAQ:CRTX)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.

Recs

0
Player Avatar or10n (< 20) Submitted: 1/22/2010 9:52:53 AM : Outperform Start Price: $5.15 CRTX Score: -20.78

trades below book value - generates revenue - solid prospects

Featured Broker Partners


Advertisement